CPHD has been the topic of several other reports. Cowen and Company downgraded Cepheid from an outperform rating to a market perform rating in a research report on Wednesday, September 7th. Barclays PLC lifted their price target on Cepheid from $36.00 to $52.00 and gave the stock an equal weight rating in a research report on Wednesday, September 7th. Zacks Investment Research raised Cepheid from a hold rating to a buy rating and set a $32.00 price target on the stock in a research report on Tuesday, June 28th. Robert W. Baird lowered Cepheid from an outperform rating to a neutral rating and set a $53.00 price objective on the stock. in a report on Monday, September 12th. Finally, Morgan Stanley started coverage on Cepheid in a report on Wednesday, June 15th. They set an equal weight rating and a $30.00 price objective on the stock. Seventeen equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $41.83.
Cepheid (NASDAQ:CPHD) traded up 0.08% on Wednesday, reaching $52.73. The company’s stock had a trading volume of 1,745,387 shares. The firm’s 50 day moving average price is $44.15 and its 200-day moving average price is $34.60. Cepheid has a 52 week low of $25.09 and a 52 week high of $53.91. The company’s market capitalization is $3.85 billion.
Cepheid (NASDAQ:CPHD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.19. The company had revenue of $146 million for the quarter, compared to the consensus estimate of $145.82 million. Cepheid had a negative return on equity of 10.20% and a negative net margin of 8.78%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) EPS. On average, equities analysts predict that Cepheid will post $0.33 EPS for the current year.
In related news, VP Scott A. Campbell sold 746 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the sale, the vice president now owns 10,721 shares in the company, valued at $393,567.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.16% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in CPHD. Societe Generale bought a new stake in Cepheid during the second quarter worth approximately $114,000. First Mercantile Trust Co. increased its stake in Cepheid by 6.6% in the second quarter. First Mercantile Trust Co. now owns 4,020 shares of the company’s stock worth $124,000 after buying an additional 250 shares in the last quarter. Globeflex Capital L P bought a new stake in Cepheid during the second quarter worth approximately $145,000. Advisor Group Inc. bought a new stake in Cepheid during the second quarter worth approximately $145,000. Finally, Independent Portfolio Consultants Inc. increased its stake in Cepheid by 10.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 5,080 shares of the company’s stock worth $156,000 after buying an additional 465 shares in the last quarter. Institutional investors and hedge funds own 95.32% of the company’s stock.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.